Medtronic (NYSE:MDT) Sets New 1-Year Low - Time to Sell?

Key Points

• Medtronic shares hit a new 52-week low of $78.29 (last $78.33) on heavy volume (~11.13M shares), trading well below its 50‑day ($88.44) and 200‑day ($94.80) moving averages.
• Analysts remain broadly positive with a consensus rating of Moderate Buy and a consensus price target of $107.80 (15 Buys, 11 Holds), though individual targets vary significantly above the current price.
• Company fundamentals show a slight beat on the latest quarter and FY2026 guidance of 5.62–5.66 EPS; Medtronic pays a $0.71 quarterly dividend (annual yield ~3.6%), and an EVP recently sold 52,524 shares.

Medtronic PLC (NYSE:MDT - Get Free Report) shares hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as $78.29 and last traded at $78.3280, with a volume of 11132273 shares changing hands. The stock had previously closed at $80.00.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. Robert W. Baird increased their price objective on shares of Medtronic from $92.00 to $93.00 and gave the company a "neutral" rating in a report on Wednesday, April 15th. Sanford C. Bernstein increased their price objective on shares of Medtronic from $111.00 to $112.00 and gave the company an "outperform" rating in a report on Friday, January 9th. Barclays increased their price objective on shares of Medtronic from $118.00 to $120.00 and gave the company an "overweight" rating in a report on Wednesday, April 1st. Wells Fargo & Company assumed coverage on shares of Medtronic in a report on Friday, January 30th. They set an "overweight" rating and a $114.00 price objective for the company. Finally, Wall Street Zen lowered shares of Medtronic from a "buy" rating to a "hold" rating in a report on Saturday, April 11th. Fifteen analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $107.80.

Medtronic Stock Performance

The business's fifty day moving average is $88.44 and its two-hundred day moving average is $94.80. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57. The stock has a market capitalization of $100.56 billion, a PE ratio of 21.82, a price-to-earnings-growth ratio of 1.90 and a beta of 0.62.

Medtronic (NYSE:MDT - Get Free Report) last posted its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, beating analysts' consensus estimates of $1.34 by $0.02. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The firm had revenue of $9.02 billion during the quarter, compared to analyst estimates of $8.89 billion. During the same period last year, the firm posted $1.38 earnings per share. Medtronic's revenue for the quarter was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, research analysts anticipate that Medtronic PLC will post 5.57 EPS for the current fiscal year.

Medtronic Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, April 17th. Investors of record on Friday, March 27th were issued a $0.71 dividend. The ex-dividend date of this dividend was Friday, March 27th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.6%. Medtronic's dividend payout ratio (DPR) is 79.11%.

Insider Buying and Selling at Medtronic

In related news, EVP Harry Skip Kiil sold 52,524 shares of the firm's stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total value of $5,132,120.04. Following the completion of the transaction, the executive vice president directly owned 32,768 shares of the company's stock, valued at approximately $3,201,761.28. This trade represents a 61.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 0.26% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Curbstone Financial Management Corp lifted its position in Medtronic by 1.8% in the fourth quarter. Curbstone Financial Management Corp now owns 5,594 shares of the medical technology company's stock worth $537,000 after buying an additional 100 shares during the last quarter. New England Capital Financial Advisors LLC lifted its position in Medtronic by 7.8% in the fourth quarter. New England Capital Financial Advisors LLC now owns 1,403 shares of the medical technology company's stock worth $135,000 after buying an additional 101 shares during the last quarter. Ipsen Advisor Group LLC lifted its position in Medtronic by 1.7% in the fourth quarter. Ipsen Advisor Group LLC now owns 5,952 shares of the medical technology company's stock worth $572,000 after buying an additional 101 shares during the last quarter. Quadrant Capital Group LLC lifted its position in Medtronic by 0.3% in the fourth quarter. Quadrant Capital Group LLC now owns 32,477 shares of the medical technology company's stock worth $3,120,000 after buying an additional 101 shares during the last quarter. Finally, Baker Tilly Wealth Management LLC lifted its position in Medtronic by 3.3% in the fourth quarter. Baker Tilly Wealth Management LLC now owns 3,221 shares of the medical technology company's stock worth $309,000 after buying an additional 102 shares during the last quarter. 82.06% of the stock is owned by hedge funds and other institutional investors.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.